Analysed DR. REDDY'S LABORATORIES-ADR (RDY:NYSE) News Sources
Asian Equities Traded in the US as American Depositary Receipts Fall in Friday Trading
05-06-2026
yahoo.com
Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States
13-06-2026
yahoo.com
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading
18-06-2026
yahoo.com
Dr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form 20-F
26-06-2026
yahoo.com
Dr. Reddy's Laboratories Flags Semaglutide Supply Delay, Says No Recall Risk
12-07-2026
marketbeat.com
Dr Reddy's Laboratories Ltd (RDY) Q1 2027 Earnings Call Highlights: Navigating Challenges and ...
28-07-2026
yahoo.com
Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States
04-08-2026
yahoo.com
What is the current price of DR. REDDY'S LABORATORIES-ADR (RDY:NYSE)?
The current price of DR. REDDY'S LABORATORIES-ADR (RDY:NYSE) is $11.68.
DR. REDDY'S LABORATORIES-ADR (RDY:NYSE) absolute price change since previous trading day?
The absolute price change of DR. REDDY'S LABORATORIES-ADR (RDY:NYSE) since the previous trading day is $0.13.
DR. REDDY'S LABORATORIES-ADR (RDY:NYSE) percentage price change since previous trading day?
The percentage price change of DR. REDDY'S LABORATORIES-ADR (RDY:NYSE) since the previous trading day is 1.1255%.
What is the most recent average sentiment score for DR. REDDY'S LABORATORIES-ADR (RDY:NYSE)?
The most recent average sentiment score for DR. REDDY'S LABORATORIES-ADR (RDY:NYSE) is 40 out of 100.
What is the most recent average sentiment for DR. REDDY'S LABORATORIES-ADR (RDY:NYSE)?
The most recent sentiment for DR. REDDY'S LABORATORIES-ADR (RDY:NYSE) is .
SEC-8K** Filing Available For DR. REDDY'S LABORATORIES-ADR (RDY:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.